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Abstract 
SUBSTANCE ABUSE AND PSYCHOSOCIAL FACTORS IN THE HEPATITIS C 
POPULATION: IDENTIFYING RISK FACTORS IN DISEASE SEVERITY AND 
QUALITY OF LIFE 
By Jill C. Clarida, M.S. 
A dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctorate of Philosophy at Virginia Commonwealth University 
Virginia Commonwealth University, 2005 
Major Directors: Karen Ingersoll, Ph.D., Assistant Professor, 
Department of Psychiatry, Internal Medicine, & Psychology 
Sandra Gramling, Ph.D., Associate Professor, 
Department of Psychology 
Hepatitis C is the most common chronic blood-borne infection in the United 
States. Research has focused on contributing factors to the development and progression 
of liver disease, but few studies have considered nicotine use as a potential prognostic 
factor with CHC. Research has commonly found that CHC patients report with a 
diminished quality of life. Several factors have been proposed to account for a decrease 
in QOL; however, the mechanisms underlying the impairment in QOL have not yet been 
elicited. 76 CHC patients completed self-report measures on a variety of psychosocial 
variables and biochemical data for determining the patient's liver disease severity was 
obtained. 
The findings revealed strong support for the deleterious effects of smoking 
cigarettes on liver disease symptomatology and it's progression. Smokers endorsed 
experiencing significantly more severe symptoms of fatigue, poor appetite, and 
headaches. The CHC smokers tended to present with higher scores on the Aspartate 
xii 
Arninotransferase to platelet ratio index (APRI). The smokers' mean score is above the 
cut-off value of 1.50 that indicates a .88 predictive value for the presence of hepatic 
fibrosis. The level of cigarette consumption could also be a factor in the progression of 
liver disease. Individuals smolung more than one pack per day tended to report more 
severe symptoms of fatigue and a poorer appetite. Heavy smokers presented with an 
APRI mean score above the cut-off value of 2.00 that indicates a .93 negative predictive 
value for the presence of cirrhosis below the cut-off value. 
General active coping moderated the relationship between liver disease severity 
and QOL. The results revealed that patients using more avoidant coping reported lower 
levels of QOL on the physical and mental component of the SF-36. Tobacco use 
moderated the relationship between liver disease severity and QOL. Interestingly, 
smokers reported a higher level of QOL compared to nonsmokers when experiencing 
more severe liver disease. CHC patients with higher levels of psychological distress 
reported lower QOL on both physical and mental functioning. Individuals smolung 
marijuana also tended to report lower levels of QOL on mental functioning. Information 
garnered from this study is aimed to help slow the progression of advanced liver disease 
in CHC patients in addition to improving their QOL. 
Introduction 
Increasing emphasis is placed on quality of life (QOL) issues in health care 
practice and research today. In 1948, the World Health Organization made mention of the 
importance of quality of life in defining health as "a state of complete physical, mental, 
and social well-being, and not merely the absence of disease or infirmity." Quality of life 
assessments have been used to measure changes in physical functioning, mental, and 
social health in order to evaluate efficacy, cost effectiveness, and benefits of new 
therapies. In recent years, quality of life variables such as physical functioning or the 
extent to which health interferes with a variety of activities and mental health, including 
general mood and psychological well-being, have become well established as important 
outcomes in medical care. This has been especially true in the area of chronic diseases for 
which there are no cures. Researchers have demonstrated that the ability to maintain well- 
being in these different domains is essential to higher quality of life for individuals with 
chronic illnesses such as cancer and AIDS (Ben-Zur, Gilbar, & Lev, 2001; Schlenk, 
Erlen, Dunbar-Jacob et al., 1998). 
Chronic hepatitis C (CHC) is one disease that has been receiving significant 
attention in quality of life research. Research has found a diminished quality of life 
across various stages of liver disease progression in CHC. Individuals with CHC 
infection may have specific fears including abandonment, pain, death, and the exposure 
of their drug use or unsafe sexual activity. Uncertainties of the outcome of the infection 
can lead to anxiety and depression. For substance abusing patients, psychological distress 
may lead them to increase substance use or relapse that will most often produce 

























































































































































































